Inclusion |
|
|
|
|
|
Age |
≥ 18 years |
≥ 18 years |
≥ 18 years |
≥ 18 years |
≥ 21
years |
AF |
Non-valvular atrial fibrillation |
Atrial fibrillation |
Non-valvular atrial fibrillation |
Atrial fibrillation or atrial flutter |
Paroxysmal, persistent, or permanent AF |
CHADS2 Score
|
CHADS2 score ≥ 2
|
One of the following:
1. Prior stroke, TIA or SE 2. EF<40%
3. HF
4. Age≥75.
5. 65≦age<75&(DM or HT or CAD)
|
CHADS2 score ≥ 2
|
CHADS2 score ≥ 1
|
CHADS2 score ≥ 2
|
Exclusion |
|
|
|
|
|
Bleeding Risk |
History of major bleeding |
History of major bleeding |
History of major bleeding |
N/A |
History of major
bleeding |
Uncontrolled hypertension
|
SBP >180mmHg or
DBP >100mmHg
|
SBP > 180mmHg and/or
DBP > 100mmHg
|
SBP ≥ 180mmHg or
DBP ≥ 100mmHg
|
SBP >180mmHg or
DBP > 100mmHg
|
SBP > 170mmHg or
DBP > 100mmHg
|
Renal function |
Calculated CLCR < 30 mL/min |
Calculated CLCR
≤ 30 mL/min |
Calculated CLCR < 30 mL/min |
Serum creatinine
> 2.5 mg/dL or a calculated CLCR < 25 |
Calculated CLCR < 30 mL/min |
Hepatic function
|
ALT or AST > 2x the ULN, or TBL ≥ 1.5x the ULN
|
Active liver disease, including but not limited to a. persistent ALT,
AST, Alk Phos > 2x the ULN
|
Known significant liver disease,
or ALT > 3x the ULN
|
ALT or AST > 2x the ULN, or a Total Bilirubin ≥ 1.5x the
ULN
|
Active or persistent liver disease, positive hepatitis B to C test, in:
・ALT or AST ≥ 2x the ULN
・TBL ≥ 1.5x the ULN
|
Haemoglobin & platelet count
|
Hgb < 10 g/dL or platelet count < 100,000
cells/mL
|
Hgb < 10 g/dL or platelet count < 100,000
cells/mL
|
Hgb < 10 g/dL or platelet count < 90,000
cells/mL
|
Hgb < 9 g/dL or platelet count ≤ 100,000 cells/mL
|
Hgb < 10 g/dL or platelet count < 100,000 cells/mL
or
WBC < 3000cell/mL
|
Antiplatelet therapy |
Aspirin in combination with thienopyridines |
N/A |
Aspirin > 100 mg/day or Aspirin in combination with
thienopyridines |
Aspirin > 165 mg/day or Aspirin in
combination with thienopyridines |
Aspirin in combination with
thienopyridines |
Anti-inflammatory agents |
Chronic treatment with NSAIDs |
N/A |
Anticipated need for chronic treatment with NSAIDs |
N/A |
Chronic
treatment with NSAIDs |
Concomitant Therapy
|
|
N/A
|
CYP3A4 inducer
CYP3A4 inhibitor
|
CYP3A4 inhibitor
Macrolide antibiotics
|
Cox-2 inhibitor
|
Drug or alcohol dependence |
Alcohol dependence |
N/A |
Drug addiction
or alcohol dependence |
Drug addiction or alcohol dependence |
Drug
addiction or alcohol dependence |